Moderna mulls increasing largest biotech IPO since 2016

Shutterstock photo

Dec 6 (Reuters) - Moderna Inc is considering selling up to 20 percent more shares than originally planned in its initial public offering on Thursday, allaying fears that stock market jitters could derail the biggest flotation of a biotechnology company since 2016, two people familiar with the matter said.

Moderna had originally planned to sell 21.7 million shares for between $22 and $24 per share. The IPO is still expected to come within that price range, said the sources, asking not to be identified because the deliberations are private, and cautioning that no final decision had been made.

Moderna did not immediately respond to a request for comment.

This article appears in: World Markets , US Markets , Stocks , IPOs
Referenced Symbols: MRNA

More from Reuters


See Reuters News

Research Brokers before you trade

Want to trade FX?